A Study of Tumor-Agnostic MRD Detection in Stage III Colorectal Cancer

Condition(s) studied

Investigational drug(s) / intervention(s)

MRD detection: Baseline blood samples, surgical resected tumor tissue, blood samples after surgery, and blood samples after adjuvant therapy will be collected from colorectal patients. MRD will be assessed using both tumor-informed and tumor-agnostic methods.

Study summary

This observational study aims to evaluate the predictive performance of various omics-based methods for detecting minimal residual disease (MRD) in stage III colorectal cancer. The study involves the collection of blood samples from patients who have accepted surgery for colorectal cancer. Blood samples will be analyzed using both tumor-informed and tumor-agnostic approaches to detect circulating tumor DNA (ctDNA). The study will compare the sensitivity of these methods and assess their correlation with recurrence risk. The findings aim to inform the development of optimal MRD detection strategies, ultimately providing a robust molecular basis for personalized treatment decisions.

Eligibility

Primary outcome measure(s)

• The predictive role of MRD in prognosis — 3 years
  The survival difference between MRD positive and MRD negative patients.

Trial sites (1)

More Sun Yat-sen University trials in China

Other trials for the same condition